Clinical trials show promise for Innocell cancer vaccine
PhotonPharma’s Innocell involves sampling a patient’s tumor cells, inactivating them so that they are unable to replicate, then administering them back to the patient. Innocell provides tumor-specific neoantigen targets for the body to identify and attack. Once the immune system identifies neoantigens, it attacks cancers displaying them throughout the body while ignoring self-antigens on healthy cells. The key break-through is our ability to target specific DNA base pairs to permanently break the DNA chains while leaving the inactivated tumor cell fully intact to provide a target for the immune system. Because Innocell uses a patient’s own tumor cells, they receive personalized therapy against their specific cancer. Neoantigen cancer vaccine strategies have resulted in significantly improved overall survival in clinical trials over the past four years.